SCHEMBL4944965

SCHEMBL4944965

N=C(N)NC(=O)c1ccc(-c2c(F)cccc2Cl)o1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR4 O95977 1/20 0.45
KMT2A Q03164 3/20 0.42
LMNA P02545 3/20 0.42
MAPK1 P28482 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MEN1 O00255 2/20 0.42
CASP3 P42574 2/20 0.42
SENP7 Q9BQF6 2/20 0.42
HPGD P15428 2/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
MAPT P10636 2/20 0.41
TP53 P04637 1/20 0.41
THRB P10828 1/20 0.41
PDE4B Q07343 3/20 0.40
RAB9A P51151 2/20 0.40
RECQL P46063 1/20 0.40
ATM Q13315 1/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4943942 0.91 PDE4B (0.47) S1PR4KMT2AMAPK1SMN1; SMN2HPGD
SCHEMBL4943949 0.80 SLC9A1 (0.61) KMT2ALMNAMAPK1SMN1; SMN2MEN1
SCHEMBL4945173 0.80 SLC9A1 (0.61) S1PR4KMT2ALMNAMAPK1SMN1; SMN2
SCHEMBL4952806 0.79 RAB9A (0.60) KMT2AMAPK1SMN1; SMN2HPGDMAPT
SCHEMBL4942987 0.79 RAB9A (0.63) KMT2ALMNAMAPK1SMN1; SMN2MEN1
SCHEMBL4946641 0.79 SLC9A1 (0.57) S1PR4KMT2ALMNAMAPK1MEN1
SCHEMBL4948212 0.78 SETD7 (0.46) S1PR4KMT2ALMNASMN1; SMN2MEN1
SCHEMBL4944971 0.77 SLC9A1 (0.64) SLC9A1
SCHEMBL3707411 0.77 SLC9A1 (0.54) S1PR4KMT2ALMNAMAPK1SMN1; SMN2
SCHEMBL4948227 0.75 KMT2A (0.43) S1PR4KMT2ALMNAMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351843-B2 Furancarbonylguanidine derivatives, their preparation and pharmaceutical compositions containing them KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2008-04-01 US claimed
US-20070299131-A1 Furancarbonylguanidine Derivatives, Their Preparation and Pharmaceutical Compositions Containing Them KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2007-12-27 US claimed
US-7351843-B2 Furancarbonylguanidine derivatives, their preparation and pharmaceutical compositions containing them KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2008-04-01 US disclosed
US-20070299131-A1 Furancarbonylguanidine Derivatives, Their Preparation and Pharmaceutical Compositions Containing Them KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2007-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299131-A1 Furancarbonylguanidine Derivatives, Their Preparation and Pharmaceutical Compositions Containing Them SLC9A1, NHERF1, SLC5A1 S1PR4 2223/4885KMT2A 4059/4885LMNA 4022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.